The primary role of Defcort (deflazacort), which belongs to the corticosteroid class, is used to help manage symptoms related to systemic imbalance and inflammatory or irritative states.

Defcort is commonly used across conditions characterized by periods of heightened symptoms, including Duchenne Muscular Dystrophy (DMD), rheumatoid arthritis, systemic lupus erythematosus (SLE), and severe persistent asthma. The medication is applied across therapeutic domains where additional symptomatic support is needed to address symptoms that create noticeable physiological strain, particularly inflammation-driven joint pain, swelling, and stiffness.

For patients coping with chronic illness, this supportive relief helps ease the overall symptom burden and may assist with supporting functional stability. In the specialized context of DMD, the medication may assist with managing symptoms related to progressive muscle weakness by supporting functional outcomes. Defcort is also relevant in clinical settings that involve acute or unstable symptom patterns, such as managing intense symptoms in certain forms of nephrotic syndrome or severe conditions involving inflammatory or irritative states.

---

Quick Fact: Relief for Systemic Inflammatory Symptoms Defcort is commonly used to help manage symptoms related to systemic imbalance and inflammatory or irritative states that often accompany chronic autoimmune and rheumatic diseases.

Eligibility Map: Who can and cannot use Defcort — Official Regulatory Information

Eligibility Scope	Detail from Official Regulatory Documents
Populations for whom use is allowed	Approved for use in patients 2 years of age and older. Available for adults and children in various authorized glucocorticoid indications.
Populations for whom use is contraindicated	Patients with known hypersensitivity to deflazacort or any inactive ingredient must not use the medicine. It is also contraindicated for patients with systemic fungal infections and for those receiving live or live-attenuated vaccines.
Age-related eligibility rules	Efficacy and safety are not established in children under 2 years of age. Older adults may be at increased risk for serious consequences associated with common corticosteroid effects.
Condition-specific eligibility rules	Severe hepatic impairment patients have no established dosage recommendations, meaning use is not established. No dosage adjustment is needed for renal impairment.
Pregnancy and lactation eligibility status	Use is not recommended during pregnancy or lactation unless the potential benefit outweighs the risk due to insufficient human data.

---

Official Eligibility Statements:

• The drug is contraindicated in patients with a known hypersensitivity to the active ingredient.
• It is contraindicated in patients with systemic fungal infections or those receiving live vaccines.
• Special caution and monitoring are required for patients with co-existing conditions such as hypertension, diabetes mellitus, and specific gastrointestinal disorders (e.g., peptic ulcers) due to increased risks.

Connection to the overall eligibility profile: The regulatory profile strictly defines who can and cannot use the medicine by listing absolute contraindications (e.g., hypersensitivity and fungal infections) and by establishing specific age restrictions (approved for ages 2 and older). Use is further governed by conditional statements requiring caution for patients with certain pre-existing conditions and is not recommended during pregnancy or for those with severe hepatic impairment where use is not established.

Interactions with other medicines and products

Deflazacort, a synthetic glucocorticoid, interacts with other substances primarily through its metabolism and additive physiological effects. All interaction statements below are strictly based on regulatory documentation.

---

Pharmacokinetic and Pharmacodynamic Interactions

Classification	Interacting Agents or Categories	Officially Documented Constraint
Metabolic (CYP3A4)	Strong or Moderate Inducers (e.g., Rifampin, Phenytoin)	Avoid Use is mandated, as these agents significantly reduce the systemic exposure of the active metabolite.
Metabolic (CYP3A4)	Strong or Moderate Inhibitors (e.g., Clarithromycin, Ketoconazole)	Co-administration increases the active metabolite's plasma concentration and requires dosage adjustment as defined in regulatory labeling.
Pharmacodynamic	Live or Live Attenuated Vaccines	Do Not Administer due to the risk of decreased vaccine efficacy and infection related to the drug's immunosuppressive activity.
Pharmacodynamic	Anti-diabetic Drugs	Deflazacort may reduce the therapeutic effect of these agents by raising blood glucose levels.

---

Additional Restrictions

The co-administration with Potassium-Depleting Agents (e.g., Thiazide Diuretics) necessitates monitoring for the additive risk of hypokalemia. Similarly, concurrent use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) requires monitoring due to the potential for increased gastrointestinal toxicity. Furthermore, co-ingestion with Grapefruit or Grapefruit Juice is explicitly restricted as it may increase the drug’s plasma levels. Interaction studies have not been conducted in patients with severe hepatic impairment.

Deflazacort is an inactive prodrug that undergoes rapid deacetylation by plasma esterases upon systemic absorption, yielding the pharmacologically active metabolite, 21-desacetyldeflazacort. This active metabolite functions as an agonist of the ubiquitous intracellular Glucocorticoid Receptor (GR).

Following binding, the activated drug-GR complex translocates into the cell nucleus. Within the nucleus, it modulates gene transcription through two primary mechanisms: transactivation and transrepression. Transactivation involves binding to specific DNA sequences known as Glucocorticoid Response Elements (GREs), leading to the upregulation of transcription for various anti-inflammatory proteins, such as Annexin A1 (lipocortin-1).

Conversely, transrepression involves protein-protein interaction, where the GR complex inhibits the activity of pro-inflammatory transcription factors, including NF-kappa B and AP-1. This dual action results in a global downstream cascade that decreases the transcription and synthesis of numerous pro-inflammatory mediators, including cytokines ( IL-1, IL-6, TNF-alpha) and chemokines. The system-level physiological consequence is a broad modulation of the immune and inflammatory processes across various tissues, coupled with metabolic alterations related to carbohydrate and protein pathways.

How to Use Defcort

Deflazacort is an anti-inflammatory and immunosuppressive synthetic glucocorticoid that is administered solely via the oral route. It is available in two main pharmaceutical preparations: tablets (in multiple strengths) and an oral suspension.

---

Official Dosing and Administration Principles

Deflazacort is typically taken once daily and may be administered with or without food.

For Duchenne Muscular Dystrophy (DMD), the standard regimen is based on body weight, set at approximately 0.9 mg/kg administered once daily. For other conditions, dosing recommendations may vary by region, with certain labels describing initial adult doses up to 120 mg/day and lower maintenance ranges.

---

Preparation and Handling

Specific instructions govern the intake of the liquid formulation. The oral suspension must be shaken well before use and the measured dose should be mixed with 3 to 4 ounces of juice or milk; it must be taken immediately after mixing. A key restriction is that grapefruit juice should not be used for mixing. Tablets can be swallowed whole or crushed and mixed with applesauce for immediate consumption.

Long-Term Use and Adjustments

If deflazacort therapy lasts for more than a few days, the official protocol requires that the dosage must be gradually reduced (tapered) before it is fully discontinued. Furthermore, when certain CYP3A4 inhibiting medications are co-administered, the deflazacort dose must be reduced to one-third of the recommended amount to account for altered exposure. No dose adjustment is generally required for mild or moderate renal or hepatic impairment.

Research Evidence / Overview of Studies for Defcort (Deflazacort)

Research evidence for Deflazacort centers on evaluating its use in conditions characterized by outcomes related to systemic or functional imbalance, particularly where outcomes linked to inflammatory or irritative states are present. Clinical evaluation includes randomized trials, observational studies, and systematic reviews, which was studied for their potential to contribute to the broader evidence landscape.

---

Evidence for Use in Duchenne Muscular Dystrophy (DMD)

The main research conducted involves short-term, placebo-controlled clinical trials and longer-term, non-randomized observational cohorts applied in populations of ambulatory male children and adolescents with DMD. Research examined outcomes reflecting daily functioning or activity level. Findings from initial trials described differences measured in functional motor assessments when compared to the placebo arm. Observational data show patterns related to the age at which key functional milestones, like the loss of independent walking, occurred.

Certainty remains low regarding the full long-term functional characteristics, as long-term effects are not fully established through prospective, controlled studies.

---

Evidence for Use in Nephrotic Syndrome

Clinical trials and systematic reviews have studied Deflazacort in pediatric patients with nephrotic syndrome, monitoring outcomes capturing phases of heightened symptom activity, such as time required to achieve remission and frequency of subsequent relapse episodes. Trials described similar rates of achieving remission compared to other standard corticosteroids. Research also focused on physiological outcomes, describing that the use of Deflazacort, when compared to other agents, was associated with differences measured in bone mineral density.

---

What is Still Uncertain About Defcort

Sample sizes were modest in many of the comparative trials, leading to findings that were mixed or inconsistent. Comparative evidence is lacking in the context of robust, head-to-head RCTs with adequate power for long-term functional outcomes against all other standard corticosteroids. Follow-up durations were limited in many primary reports, which means long-term effects concerning the complete progression of chronic conditions are not fully established. Research contributes to understanding group patterns, but does not determine whether an individual's experience will evolve similarly.

Common questions about Defcort (FAQ)

Q: I forgot my daily dose of Deflazacort. What should I do—take it now or wait until the next dose?

According to the official guidance on taking Deflazacort, if a dose is missed, the recommended approach is to take it as soon as possible. If, however, it is nearly time for the next scheduled dose, the guidance is to skip the missed dose and return to the regular dosing schedule. It is noted that two doses should not be taken at the same time to make up for a missed dose.

---

Q: What is the maximum daily dose of Deflazacort for an adult?

Official regulatory documents indicate that for the specific, approved condition of Duchenne muscular dystrophy (DMD), the daily dose is typically calculated based on body weight. The maximum dose generally established in regulatory documents for this specific indication is approximately 36 mg/day. Dosing for other conditions may vary, and is not a recommendation for personal use.

---

Q: Is it okay to crush the Deflazacort tablet, or must I swallow it whole?

Regulatory documents state that Deflazacort tablets may be swallowed whole. They also permit the tablets to be crushed and immediately mixed with a small amount of applesauce for consumption. This instruction is provided in the official administration guidelines.

---

Q: I have a systemic bacterial infection. Can I still take my Deflazacort?

Regulatory warnings indicate that corticosteroids like Deflazacort suppress the immune system, which can increase the risk of infection from various sources. For this reason, official drug labeling notes that patients with or predisposed to infections may require careful monitoring and caution while using this medicine.

---

Q: Does the Deflazacort oral suspension need to be refrigerated after opening?

Official storage guidelines specify that both the Deflazacort tablets and oral suspension should be stored at controlled room temperature, between 68 F to 77 F (20 C to 25 C). The product information does not include a requirement for refrigeration after the bottle has been opened.

---

Q: Can Deflazacort cause weight loss?

Clinical studies detailed in the official product information list weight increased and increased appetite among the most commonly reported side effects. Weight loss is not listed among the frequent or common adverse reactions associated with Deflazacort use.

How to Store and Dispose of Deflazacort

Official regulatory guidelines mandate specific conditions for storing Deflazacort tablets and oral suspension to maintain product integrity.

Required Storage Conditions

Condition	Requirement
Temperature	Store at Controlled Room Temperature, between 68 F to 77 F (20 C to 25 C).
Protection	Keep away from excess heat, excess moisture, and do not freeze.
Container	Keep in the original container and ensure it is tightly closed.

Stability and Child Safety

Both formulations must be stored out of the sight and reach of children. The oral suspension has a critical stability limit: it must be discarded after 1 month of first opening the bottle. Disposal of any expired or unneeded medication should follow official procedures, such as utilizing a drug take-back program.